We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| GSK plc | NYSE:GSK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 38.63 | 0 | 01:00:00 |
From Oct 2019 to Oct 2024
By Cecilia Butini
GlaxoSmithKline PLC said Friday that it has submitted an application for emergency authorization at the U.S. Food and Drug Administration for a Covid-19 treatment together with Vir Biotechnology Inc.
The company said the drug, named VIR-7831, is an investigational, dual-action monoclonal antibody for the treatment of adults and adolescents with mild-to-moderate Covid-19 who are at risk for progression to hospitalization or death.
The submission is based on data from a Phase 3 clinical trial named COMET-ICE.
GlaxoSmithKline and Vir will continue discussions with the European Medicines Agency and other regulators around the world to make the drug available, Glaxo said.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
March 26, 2021 08:44 ET (12:44 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
